Veradermics, Incorporated
MANE
$98.86
-$4.98-4.79%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Net Income | -23.50M | -27.23M | -21.85M | -15.65M | |
| Total Depreciation and Amortization | -- | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 4.21M | 5.81M | 820.00K | 370.00K | |
| Change in Net Operating Assets | 4.81M | 251.00K | -2.60M | -368.00K | |
| Cash from Operations | -14.49M | -21.17M | -23.63M | -15.64M | |
| Capital Expenditure | -21.00K | -- | -5.00K | 0.00 | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -277.27M | -101.30M | -109.77M | -8.33M | |
| Cash from Investing | -277.29M | -101.30M | -109.78M | -8.33M | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 414.58M | 269.11M | -- | 129.00K | |
| Repurchase of Common Stock | -- | -- | -1.05M | -- | |
| Issuance of Preferred Stock | -- | -- | 151.00M | 0.00 | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 28.12M | -- | -437.00K | -- | |
| Cash from Financing | 442.70M | 269.11M | 149.51M | 129.00K | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 150.92M | 146.65M | 16.11M | -23.84M | |